Diabetes Therapeutics Market Expansion Outlook: $252.95 Billion by 2029 Forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Diabetes Therapeutics Market By 2029?

The diabetes therapeutics market has seen swift growth in recent years. It is projected to increase from $153.67 billion in 2024 to $170.06 billion in 2025, at a compound annual growth rate (CAGR) of 10.7%. This historical expansion can be attributed to several factors, including an initial rise in diabetes prevalence, the widespread application of oral hypoglycemic agents, the early uptake of injectable insulin therapies, greater emphasis on education for self-management, and the introduction of biosimilar insulins into the market.

The diabetes therapeutics market size is anticipated to experience substantial growth over the next few years. It is forecast to expand to $252.95 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.4%. This growth during the forecast period is primarily driven by increasing digital literacy, a rise in the adoption of injectable non-insulin drugs, the expansion of digital health platforms, growing demand for personalized and combination therapies, and improvements in healthcare infrastructure and access to diabetes care. Significant trends for the forecast period include automated insulin delivery (AID) systems, the integration of artificial intelligence (AI) in diabetes care, enhanced interoperability of devices, the development of digital health apps, and remote patient monitoring (RPM).

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25749&type=smp

Which Drivers Are Impacting The Diabetes Therapeutics Market?

The increasing prevalence of obesity is anticipated to boost the growth of the diabetes therapeutics market moving forward. Obesity, defined as excessive fat accumulation posing a health risk, stands as a primary risk factor for type 2 diabetes. The escalating incidence of obesity is attributed to heightened consumption of high-calorie diets, with more individuals opting for processed and fast foods rich in sugar and fat, alongside reduced physical activity, culminating in excessive weight gain. Diabetes therapeutics play a role in managing obesity by facilitating blood sugar control and supporting weight loss through medications such as GLP-1 receptor agonists, which work by suppressing appetite and slowing digestion, thereby enhancing the overall metabolic health of obese individuals. For instance, in May 2024, a report published by the Office for Health Improvement and Disparities, a UK-based government department, indicated that in 2022 to 2023, approximately 64% of adults aged 18 and over were categorized as overweight or living with obesity, marking an increase from the previous year’s figure of 63.8%. Consequently, the rising prevalence of obesity is a key driver for the expansion of the diabetes therapeutics market.

How Is The Diabetes Therapeutics Market Segmented?

The diabetes therapeutics market covered in this report is segmented –

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug

2) By Type: Diabetes 1, Diabetes 2

3) By Route Of Administration: Oral, Subcutaneous, Intravenous

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

5) By Application: Preventive, Treatment Or Care

Subsegments:

1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors

2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs

4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

Which Market Trends Are Creating New Opportunities In The Diabetes Therapeutics Industry?

Prominent companies within the diabetes therapeutics market are channeling their efforts into pioneering solutions, such as cognitive behavioral therapy (CBT), designed to elevate personalized diabetes management and refine glycemic control for patients living with type 2 diabetes. Cognitive behavioral therapy (CBT) constitutes a structured, evidence-backed psychological treatment that aids individuals in discerning and modifying counterproductive thought patterns and actions. Illustratively, in October 2023, Better Therapeutics Inc., a US-based digital therapeutics company, released AspyreRx, a digital diabetes therapeutic application. AspyreRx, which secured FDA authorization for addressing type 2 diabetes, delivers bespoke cognitive behavioral therapy (CBT) to patients aged 18 and older, thereby facilitating behavioral alterations conducive to improved diabetes management. Formerly recognized as BT-001, AspyreRx exhibited statistically and clinically meaningful, sustained reductions in A1c when benchmarked against standard care, accompanied by enhancements in blood pressure, weight, mood, and overall quality of life, as observed in a randomized controlled trial.

Which Major Industry Participants Are Leading The Diabetes Therapeutics Market Growth?

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Tandem Diabetes Care Inc., Lexicon Pharmaceuticals Inc., Better Therapeutics Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/diabetes-therapeutics-global-market-report

How Is Diabetes Therapeutics Market Demand Varying Across Different Regions?

North America was the largest region in the diabetes therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Diabetes Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25749&type=smp

Browse Through More Reports Similar to the Global Diabetes Therapeutics Market 2025, By The Business Research Company

Antidiabetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Insulin Therapies For Diabetes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Antidiabetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795